SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million (the “Stockholders’ Equity Requirement”).
Helicopter will be onsite for racers and crew members needing emergency air transport Life Saver…
A Leader of Technology-Enabled Water Solutions Has Welcomed Three Companies This YearST. LOUIS, April 21, 2025…
ST. PETERSBURG, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- With Earth Day on the horizon,…
DigitCells, an innovator at the forefront of comprehensive pathology solutions, and Mindpeak, a pioneering force…
GUELPH, Ontario, April 21, 2025 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS” or the…
ThriftBooks Expands BuyBack Program to Serve Bulk Booksellers Nationwide ThriftBooks Logo three teal books above…
This website uses cookies.